HIV Pre-exposure prophylaxis and Resistance - PrEPaRe Version 1.0
Research type
Research Study
Full title
Pre-exposure prophylaxis use in people newly diagnosed with HIV
IRAS ID
265346
Contact name
Ann Sullivan
Contact email
Sponsor organisation
CHIP - Centre of Excellence for Health, Immunity and Infections
Duration of Study in the UK
2 years, 7 months, 31 days
Research summary
Pre-exposure prophylaxis (PrEP) is when antiretroviral medication (medication usually taken to treat HIV infection) is taken by people not infected with HIV to prevent HIV acquisition. It has been shown to be highly efficacious, effective and cost-effective within specific population groups in Europe. However, people unknowingly infected with HIV can develop resistance to antiretroviral therapy if they start or continue to use PrEP after they are infected. The PrEPaRe study is an observational study collecting individual level data on people newly diagnosed with HIV and who report having used PrEP. The aim is to understand the circumstances under which these HIV infections occurred and to estimate the prevalence of HIV drug resistance in those people who have taken PrEP.
Aggregate data on the number of people newly diagnosed with HIV will also be collected in order to assess the use of PrEP among people newly diagnosed with HIV. Data will be collected from clinics across Europe (including the UK); the clinics involved will be those clinics where HIV is diagnosed and/or HIV care is delivered.REC name
South Central - Hampshire A Research Ethics Committee
REC reference
20/SC/0044
Date of REC Opinion
7 Feb 2020
REC opinion
Favourable Opinion